Insights from the world of cardiology
For healthcare professionals only
This supplement is a report from the inaugural meeting of the Cardiometabolic Forum, jointly organised by the British Journal of Cardiology and HEART UK – The Cholesterol Charity. The meeting was held at the Royal Pharmaceutical Society, London, on 24th November 2011. Meeting chairs were Dr Dermot Neely (Royal Victoria Infirmary, Newcastle upon Tyne) for HEART UK, and Dr Henry Purcell (Royal Brompton Hospital, London, and Editor) for BJC.
We hope this supplement will provide readers with an independent overview on recent developments in our knowledge of cholesterol metabolism and its implications for clinical practice.
Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Victoria Infirmary, Newcastle upon Tyne
Kausik K Ray
Professor of Cardiovascular Disease Prevention, St. George’s Hospital, University of London
Consultant Endocrinologist, Honorary Reader in Medicine, University of Bath, and Honorary Professor, Robert Gordon University, Aberdeen
Consultant Community Cardiologist, Royal Victoria Infirmary, Newcastle upon Tyne
Honorary Consultant, Cambridge University Hospitals NHS Trust, Lister Hospital, Stevenage
Disclaimer: Medinews Cardiology Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews Cardiology Limited cannot accept responsibility for any errors in prescribing which may occur.
Conflict of interest: Dr Dermot Neely has received sponsorship for travel to conferences and honoraria for advisory boards and lectures from Astra Zeneca, Merck, Pfizer, Roche Pharmaceuticals and Sanofi-Aventis; he has received research grants from Pfizer and Schering Plough. Professor Kausik K Ray has received honoraria for advisory boards and lectures from Abbott, Astra Zeneca, BMS, Kowa, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sankyo and Sanofi-Aventis. Professor John Reckless has served on advisory boards, had speaker engagements and received meeting travel support from pharmaceutical companies in the lipid and diabetes fields, but these do not relate to this supplement. He is a Trustee of HEART UK, the national Cholesterol Charity. He was a committee member of the National Institute for Health and Clinical Excellence (NICE) CG67 lipid modification guideline. Dr Jane Skinner was clinical advisor to the National Institute for Health and Clinical Excellence (NICE) for the post MI secondary prevention and chest pain guidelines. She has received travel bursaries from Roche and Sanofi Aventis. Dr Adie Viljoen has received honoraria for participation in advisory boards and lectures and is a clinical investigator in trials funded by Astra Zeneca, Eli Lilly, MannKind, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis and Takeda.